

Quarterly Disclosure Statements
(Unaudited)
For the Six Months Ended June 30, 2023
For



Advocate Aurora Health, Inc.



The Charlotte-Mecklenburg Hospital Authority Combined Group



Wake Forest Baptist Combined Group

Investor Relations Contact:
Jenny Temple, VP Treasury and Assistant Treasurer
Email: jennifer.temple@atriumhealth.org

# ADVOCATE HEALTH, INC. TABLE OF CONTENTS

INTRODUCTION:	<u>2</u>
ADVOCATE HEALTH:	
<u>Introduction</u>	<u>3</u>
Combined Balance Sheet	<u>4</u>
Combined Statement of Operations and Changes in Net Assets	<u>5</u>
Combined Statement of Cash Flows	<u>7</u>
<u>Utilization Statistics</u>	<u>8</u>
ADVOCATE AURORA HEALTH, INC:	
<u>Introduction</u>	<u>9</u>
Consolidated Financial Statements	<u>10</u>
<u>Utilization Statistics</u>	<u>15</u>
THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A ATRIUM HEALTH COMBINED GROUP:	
<u>Introduction</u>	<u>16</u>
<u>Financial Highlights</u>	<u>17</u>
Combined Financial Statements	<u>18</u>
<u>Utilization Statistics</u>	<u>21</u>
ATRIUM HEALTH WAKE FOREST BAPTIST COMBINED GROUP:	
<u>Introduction</u>	<u>22</u>
Combined Financial Statements	<u>23</u>
Combining Financial Statements	<u>26</u>
<u>Utilization Statistics</u>	<u>28</u>

#### Introduction

#### **Purpose of this Report**

The purpose of this report is to provide information necessary to comply with continuing disclosure undertakings with respect to the Advocate Aurora Health Credit Group, The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health Combined Group and the Atrium Health Wake Forest Baptist Combined Group, as described below, all of which are now part of an integrated health care delivery and academic system known as Advocate Health.

#### **Advocate Health**

Effective December 2, 2022, Advocate Aurora Health, Inc., a Delaware nonprofit corporation ("AAH") and Atrium Health, Inc., a North Carolina nonprofit corporation ("AHI"), entered into a Joint Operating Agreement pursuant to which they created Advocate Health, Inc., a Delaware nonprofit corporation (the "Advocate Health JOC"), to manage and oversee Advocate Health, which will focus on meeting patients' needs by redefining how, when, and where care is delivered. AAH and AHI are the two corporate members of the Advocate Health JOC. AAH and the entities comprising the "AAH System" described below (the "AAH System Entities") and AHI and the other participants in the "AHI Enterprise" described below (the "AHI Enterprise Entities") have maintained their separate legal existence and no sale, transfer, or other conveyance of their assets occurred in connection with the formation of Advocate Health. No assumption or guaranty of debt or other liabilities of the AAH System Entities or AHI Enterprise Entities, or changes to their respective credit groups described below, occurred in connection with the formation of Advocate Health. Advocate Health has a combined footprint across Illinois, Wisconsin, North Carolina, South Carolina, Georgia, and Alabama.

#### Advocate Aurora Health, Inc.

AAH is the sole corporate member of Advocate Health Care Network, an Illinois not for profit corporation, ("Advocate") and Aurora Health Care, Inc., a Wisconsin nonstock not-for-profit corporation ("Aurora"). AAH, Advocate, Aurora, and their controlled subsidiaries are collectively referred to herein as the "AAH System." The AAH System serves patients across northern and central Illinois and eastern Wisconsin. The participants in the AAH System do business as Advocate in Illinois and as Aurora in Wisconsin.

#### Atrium Health, Inc.

In October 2020, The Charlotte-Mecklenburg Hospital Authority ("CMHA" or "Atrium Health CMHA"), which directly and through its affiliates does business as Atrium Health, and the Wake Forest Baptist Health system ("Wake Forest Baptist" or "Atrium Health Wake Forest Baptist), including Wake Forest School of Medicine, became part of a single enterprise (the "AHI Enterprise"), which is governed and managed by AHI pursuant to a health system integration agreement and related agreements. The AHI Enterprise serves patients across North Carolina, South Carolina, Georgia, and Alabama. The participants in the AHI Enterprise do business as Atrium Health and Atrium Health Wake Forest Baptist (in North Carolina and South Carolina) and as Atrium Health Navicent and Atrium Health Floyd (in Georgia and Alabama).



## Advocate Health Introduction

The financial position and results of operation of Advocate Health are presented by combining the financial statements of AAH, Atrium Health CMHA, and Atrium Health Wake Forest Baptist, which are under the common management of the Advocate Health JOC. Advocate Health, which includes Atrium Health CMHA, has prepared its financial statements in accordance with accounting principles as promulgated by the Financial Accounting Standards Board ("FASB"). Atrium Health CMHA is a governmental entity as defined by the Governmental Accounting Standards Board ("GASB"); accordingly, accounting principles as promulgated by GASB are the appropriate accounting principles for Atrium Health CMHA to follow. Preparation of the Advocate Health combined financial statements requires the financial statements of Atrium Health CMHA to be converted from presentation in accordance with GASB accounting principles to presentation in accordance with FASB accounting principles prior to combination.

The Advocate Health combined financial statements are not required to be delivered pursuant to any continuing disclosure undertaking and are being provided on a voluntary basis.

### **COMBINED BALANCE SHEET (Unaudited)**

	Ju	ine 30, 2023
Assets		
Current assets		
Cash and cash equivalents	\$	1,410,916
Short term investments		91,159
Assets limited as to use		207,689
Patient accounts receivable		3,662,596
Other current assets		1,824,800
Total current assets		7,197,160
Other assets		
Assets limited as to use		20,295,138
Property and equipment, net		12,322,355
Operating lease right-of-use assets		933,063
Other noncurrent assets		1,801,463
Total other assets		35,352,019
Total assets	\$	42,549,179
Liabilities		
Current liabilities		
Long-term debt, current portion	\$	989,311
Operating lease liabilities, current portion		179,298
Accrued salaries and employee benefits		1,996,047
Accounts payable and other accrued liabilities		2,366,533
Third-party payors payables		709,129
Total current liabilities		6,240,318
Noncurrent liabilities		
Long-term debt, less current portion		6,966,691
Operating lease liabilities, less current portion		826,994
Obligations under swap agreements		114,411
Other noncurrent liabilities		3,015,760
Total noncurrent liabilities		10,923,856
Total liabilities		17,164,174
Net assets		
Without donor restrictions		
Controlling interest		24,037,196
Noncontrolling interests in subsidiaries		179,634
Total net assets without donor restrictions		24,216,830
With donor restrictions		1,168,175
Total net assets		25,385,005
Total liabilities and net assets	\$	42,549,179

### **COMBINED STATEMENT OF OPERATIONS AND CHANGES IN NET ASSETS (Unaudited)**

	ths Ended 30, 2023
Revenue	
Patient service revenue	\$ 12,825,024
Capitation revenue	612,783
Other revenue	1,754,047
Total revenue	15,191,854
Expenses	
Salaries, wages, and benefits	8,806,575
Supplies and drugs	3,106,480
Purchased services and other expenses	2,442,183
Depreciation and amortization	603,997
Interest	146,924
Total expenses	15,106,159
Operating income	85,695
Nonoperating income	
Investment income, net	938,414
Other nonoperating income, net	2,891
Total nonoperating income, net	 941,305
Revenue in excess of expenses	1,027,000
Less income attributable to noncontrolling interests	 (29,095
Revenue in excess of expenses - attributable to controlling interest	\$ 997,905

### **COMBINED STATEMENT OF OPERATIONS AND CHANGES IN NET ASSETS (Unaudited)**

		Months Ended une 30, 2023
Net assets without donor restrictions, controlling interest		
Revenue in excess of expenses - attributable to controlling interest	\$	997,905
Pension-related changes other than net periodic pension costs		19,633
Other, net		10,258
Increase in net assets without donor restrictions, controlling interest		1,027,796
Net assets without donor restrictions, noncontrolling interests		
Revenues in excess of expenses		29,095
Distributions to noncontrolling interests		(21,252)
Increase in net assets without donor restrictions, noncontrolling interests		7,843
Net assets with donor restrictions		
Contributions		86,356
Investment income, net		43,647
Net assets released from restrictions		(75,779)
Other, net		(549)
Increase in net assets with donor restrictions	_	53,675
Increase in net assets		1,089,314
Net assets at beginning of period		24,295,691
Net assets at end of period	\$	25,385,005

### **COMBINED STATEMENT OF CASH FLOWS (Unaudited)**

	Six Months Ended June 30, 2023
Cash flows from operating activities	
Increase in net assets	\$ 1,089,314
Adjustments to reconcile change in net assets to net cash provided by operating activities:	
Depreciation, amortization, and accretion	598,811
Amortization of operating lease right-of-use assets	102,916
Gain on sale of property and equipment	(1,471)
Pension-related changes other than net periodic pension cost	(19,633)
Proceeds from restricted contributions	(51,940)
Distribution to noncontrolling interests	27,388
Other	(9,737)
Changes in operating assets and liabilities	
Trading securities, net	(674,041)
Patient accounts receivable	(77,930)
Accounts payable and accrued liabilities	(357,928)
Third-party payors receivable and payable, net	94,569
Other assets and liabilities, net	(371,213)
Net cash provided by operating activities	349,105
Cash flows from investing activities	
Capital expenditures	(627,467)
Proceeds from sale of property and equipment	644
Sales of investments designated as non-trading, net	414,749
Investments in unconsolidated entities, net	(37,178)
Other	6,682
Net cash used in investing activities	(242,570)
Cash flows from financing activities	
Repayments of long-term debt, net	(134,278)
Proceeds from issuance of long-term debt	50,000
Distribution to noncontrolling interests	(27,388)
Proceeds from restricted contributions and income on investments	66,732
Net cash used in financing activities	(44,934)
Net increase in cash and cash equivalents	61,601
Cash and cash equivalents at beginning of period	1,441,867
Cash and cash equivalents at end of period	\$ 1,503,468
Reconciliation of cash and cash equivalents to the balance sheet	
Cash and cash equivalents	1,410,916
Restricted cash in investments and assets whose use is limited	92,552
	\$ 1,503,468

## ADVOCATE HEALTH UTILIZATION STATISTICS

	Six Months Ended June 30, 2023
Census	
Discharges	252,374
Observation Cases	91,274
Total Bedded Patients	343,648
Inpatient Days	1,391,792
Inpatient Length of Stay	5.50
Case Mix index	1.82
Other Volume Stats	
Inpatient Surgeries	61,552
Outpatient Surgeries	157,720
Total Surgeries	219,272
ED Visits	1,069,126
wRVUs	26,392,345



### ADVOCATE AURORA HEALTH, INC.

Introduction

#### **Advocate Aurora Health Credit Group**

AAH and certain other AAH System Entities are members of the "Obligated Group" (the "AAH Obligated Group") created under a Second Amended and Restated Trust Indenture dated as of August 1, 2018 (the "AAH Master Indenture") among the Obligated Group Members identified therein and U.S. Bank Trust Company, National Association, Master Trustee. The members of the AAH Obligated Group are jointly and severally liable on any "Obligations" issued under the AAH Master Indenture. Certain of the AAH Obligated Group's affiliates are designated as "Restricted Affiliates" under the AAH Master Indenture.

Neither the Advocate JOA nor any of the AHI Enterprise Entities is a member of AAH Obligated Group or a Restricted Affiliate as of the date of this report and, therefore, none of them have any obligation to provide for the payment of any Obligation issued under the AAH Master Indenture.

#### **Basis of Presentation**

The accompanying consolidated financial statements for AAH as of and for the three and six months ended June 30, 2023 and 2022, have been prepared in accordance with U.S. generally accepted accounting principles, as promulgated by the Financial Accounting Standards Board ("FASB").

# ADVOCATE AURORA HEALTH, INC. CONSOLIDATED BALANCE SHEETS

	(Unaudited) June 30, 2023	(Audited) December 31, 2022		
Assets				
Current assets				
Cash and cash equivalents	\$ 615,090	\$ 372,898		
Assets limited as to use	153,152	153,557		
Patient accounts receivable	1,787,328	1,796,499		
Other current assets	995,086	975,406		
Total current assets	3,550,656	3,298,360		
Assets limited as to use	11,058,745	10,981,192		
Property and equipment, net	5,917,078	5,971,542		
Other assets				
Goodwill and intangible assets, net	442,372	476,564		
Investments in unconsolidated entities	233,144	216,176		
Reinsurance receivable	126,830	116,786		
Operating lease right-of-use assets	291,390	305,311		
Other noncurrent assets	580,248	512,339		
Total other assets	1,673,984	1,627,176		
Total assets	\$ 22,200,463	\$ 21,878,270		

# ADVOCATE AURORA HEALTH, INC. CONSOLIDATED BALANCE SHEETS

	(Unaudited) June 30, 2023		(Audited) December 31, 2022	
Liabilities				
Current liabilities				
Long-term debt and commercial paper, current portion	\$	102,661	\$	101,204
Long-term debt subject to short-term financing arrangements		118,220		165,035
Operating lease liabilities, current portion		70,460		73,026
Accrued salaries and employee benefits		1,066,590		1,165,861
Accounts payable and other accrued liabilities		979,006		1,128,954
Third-party payors payables		385,151		357,177
Accrued insurance and claims costs, current portion		207,416		204,592
Total current liabilities		2,929,504		3,195,849
Noncurrent liabilities				
Long-term debt, less current portion		3,278,276		3,255,423
Operating lease liabilities, less current portion		254,579		276,116
Accrued insurance and claims cost, less current portion		663,079		634,468
Accrued losses subject to insurance recovery		126,830		116,786
Obligations under swap agreements		29,224		29,514
Other noncurrent liabilities		975,045		922,567
Total noncurrent liabilities		5,327,033		5,234,874
Total liabilities		8,256,537		8,430,723
Net assets				
Without donor restrictions				
Controlling interest		13,525,726		13,037,580
Noncontrolling interests in subsidiaries		179,634		171,791
Total net assets without donor restrictions		13,705,360		13,209,371
With donor restrictions		238,566		238,176
Total net assets		13,943,926		13,447,547
Total liabilities and net assets	\$	22,200,463	\$	21,878,270

# ADVOCATE AURORA HEALTH, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS

(in thousands)

	(Unaudited)			(Unaudited)				
	Three Months Ended June 30, 2023		Ended June 30, Ended June 30,		Six Months Ended June 30, 2023		Six Months Ended June 30, 2022	
Revenue								
Patient service revenue	\$	3,186,715	\$	2,953,214	\$	6,388,130	\$	5,944,296
Capitation revenue		311,604		301,629		612,783		602,026
Other revenue		382,530		291,440		783,762		565,806
Total revenue		3,880,849		3,546,283		7,784,675		7,112,128
Expenses								
Salaries, wages, and benefits		2,228,328		2,092,975		4,457,733		4,176,138
Supplies, purchased services, and other		1,287,627		1,108,130		2,546,982		2,267,928
Contracted medical services		140,348		115,621		275,488		266,402
Depreciation and amortization		154,796		150,891		307,164		293,081
Interest		31,924		29,955		63,175		57,363
Total expenses		3,843,023		3,497,572		7,650,542		7,060,912
Operating income		37,826		48,711		134,133		51,216
Nonoperating income (loss)								
Investment income (loss), net		119,416		(400,030)		400,673		(665,998)
Other nonoperating loss, net		(199)		15,210		(21,586)		36,065
Total nonoperating income (loss), net		119,217		(384,820)		379,087		(629,933)
Revenue in excess of (less than) expenses		157,043		(336,109)		513,220		(578,717)
Less income attributable to noncontrolling interests		(13,236)		(11,441)		(29,095)		(22,060)
Revenue in excess of (less than) expenses - attributable to controlling interest	\$	143,807	\$	(347,550)	\$	484,125	\$	(600,777)

(Continued)

# ADVOCATE AURORA HEALTH, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS

(in thousands)

	(Unau	dited)	(Unaudited)		
	Three Months Three Months Ended June 30, Ended June 30, E 2023 2022		Six Months Ended June 30, 2023	Six Months Ended June 30, 2022	
Net assets without donor restrictions, controlling interest					
Revenue in excess of (less than) expenses - attributable to controlling interest	\$ 143,807	\$ (347,550)	\$ 484,125	\$ (600,777)	
Pension-related changes other than net periodic pension costs	702	1,854	1,401	3,664	
Net assets released from restrictions for purchase of property and equipment	1,070	965	4,635	2,405	
Other, net	(844)	(45)	(2,015)	7,982	
Increase (decrease) in net assets without donor restrictions, controlling interest	144,735	(344,776)	488,146	(586,726)	
Net assets without donor restrictions, noncontrolling interests					
Revenues in excess of expenses	13,236	11,441	29,095	22,060	
Distributions to noncontrolling interests	(7,809)	(7,145)	(21,252)	(27,270)	
Increase (decrease) in net assets without donor restrictions, noncontrolling interests	5,427	4,296	7,843	(5,210)	
Net assets with donor restrictions					
Contributions	3,802	2,276	5,918	3,336	
Investment income (loss), net	1,305	(4,701)	4,386	(8,129)	
Net assets released from restrictions for operations	(2,981)	(2,406)	(5,344)	(5,239)	
Net assets released from restrictions for purchase of property and equipment	(1,070)	(965)	(4,635)	(2,405)	
Other, net	47	(183)	65	(196)	
Increase (decrease) in net assets with donor restrictions	1,103	(5,979)	390	(12,633)	
Increase (decrease) in net assets	151,265	(346,459)	496,379	(604,569)	
Net assets at beginning of period	13,792,661	14,072,869	13,447,547	14,330,979	
Net assets at end of period	\$ 13,943,926	\$ 13,726,410	\$ 13,943,926	\$ 13,726,410	

(Concluded)

# ADVOCATE AURORA HEALTH, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS

	(Unaudited)		(Unau	dited)
	Three Months Ended June 30, 2023	Three Months Ended June 30, 2022	Six Months Ended June 30, 2023	Six Months Ended June 30, 2022
Cash flows from operating activities				
Increase (decrease) in net assets	\$ 151,265	\$ (346,459)	\$ 496,379	\$ (604,569)
Adjustments to reconcile change in net assets to net cash provided by operating activities:				
Depreciation, amortization, and accretion	152,138	146,211	301,978	285,930
Amortization of operating lease right-of-use assets	18,408	16,726	35,790	35,647
Loss on debt refinancing	_	_	40	33
Loss (gain) on sale of property and equipment	637	85	(1,380)	509
Change in fair value of swap agreements	(7,382)	(19,430)	(291)	(42,680)
Pension-related changes other than net periodic pension cost	(702)	(1,854)	(1,401)	(3,664)
Net assets released from restrictions for operations	(2,981)	(2,406)	(5,344)	(5,239)
Distribution to noncontrolling interests	19,405	19,269	27,388	39,394
Distributions from unconsolidated entities	986	266	8,056	17,265
Changes in operating assets and liabilities				
Trading securities, net	(153,653)	246,948	(82,450)	1,301,260
Patient accounts receivable	76,933	35,063	9,172	(33,894)
Accounts payable and accrued liabilities	74,564	143,049	(192,875)	(441,159)
Third-party payors receivable and payable, net	12,966	(28,260)	47,072	(25,414)
Other assets and liabilities, net	(5,110)	175	(103,925)	(79,201)
Net cash provided by operating activities	337,474	209,383	538,209	444,218
Cash flows from investing activities				
Capital expenditures	(118,204)	(112,199)	(244,276)	(241,780)
Proceeds from sale of property and equipment	343	375	513	1,033
(Purchases) sales of investments designated as non-trading, net	(24)	168	(63)	(66)
Investments in unconsolidated entities, net	(16,938)	_	(17,721)	(17,383)
Acquisition of MobileHelp, net of cash acquired	_	(285,777)	_	(285,777)
Other	(101)	(452)	(404)	(887)
Net cash used in investing activities	(134,924)	(397,885)	(261,951)	(544,860)
Cash flows from financing activities				
Repayments of long-term debt, net	(11,744)	(17,291)	(16,982)	(23,220)
Distribution to noncontrolling interests	(19,405)	(19,269)	(27,388)	(39,394)
Proceeds from restricted contributions and income on investments	5,107	(2,425)	10,304	(4,793)
Net cash used in financing activities	(26,042)	(38,985)	(34,066)	(67,407)
Net increase (decrease) in cash and cash equivalents	176,508	(227,487)	242,192	(168,049)
Cash and cash equivalents at beginning of period	438,582	763,163	372,898	703,725
Cash and cash equivalents at end of period	\$ 615,090	\$ 535,676	\$ 615,090	\$ 535,676
Supplemental disclosures of noncash information				
Operating lease right-of-use assets in exchange for new				
operating lease light-of-use assets in exchange for new	\$ 17,143	\$ 45,529	\$ 21,870	\$ 67,414

# ADVOCATE AURORA HEALTH, INC. UTILIZATION STATISTICS

	Three Months Ended June 30, 2023	Three Months Ended June 30, 2022	Change	% Change
Historical Utilization Statistics				
Discharges	60,342	58,450	1,892	3.2 %
Observation Cases	26,964	26,395	569	2.2 %
Patient Days	308,532	316,030	(7,498)	(2.4)%
<b>Hospital Outpatient Visits</b>	1,152,991	1,097,689	55,302	5.0 %
Physician Visits	2,631,630	2,486,046	145,584	5.9 %
Home Care Visits	213,918	205,818	8,100	3.9 %
Capitated Member Lives <sup>(1)</sup>	220,572	233,067	(12,495)	(5.4)%
	Six Months Ended June 30, 2023	Six Months Ended June 30, 2022	Change	% Change
Historical Utilization Statistics	-			
Discharges	119,442	115,411	4,031	3.5 %
Observation Cases	53,157	48,899	4,258	8.7 %
Patient Days	628,561	643,550	(14,989)	(2.3)%
Hospital Outpatient Visits	2,272,610	2,134,088	138,522	6.5 %
Physician Visits	5,233,283	4,877,918	355,365	7.3 %
Home Care Visits	432,890	411,044	21,846	5.3 %

 $<sup>^{\</sup>left( 1\right) }$  As of the date set forth in the column header

	Three Months Ended June 30, 2023	Three Months Ended June 30, 2022	Six Months Ended June 30, 2023	Six Months Ended June 30, 2022
Payor Mix				
Managed Care	53 %	56 %	53 %	56 %
Medicare	31 %	31 %	32 %	31 %
Medicaid	14 %	12 %	13 %	11 %
Self-pay and Other	2 %	1 %	2 %	2 %
	100 %	100 %	100 %	100 %



## THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY COMBINED GROUP Introduction

#### **Atrium Health CMHA Combined Group**

CMHA issues revenue bonds ("CMHA Bonds") under a Second Amended and Restated Bond Order adopted in 1997 (as amended, the "CMHA Bond Order"). CMHA and certain of its affiliates have formed an "Obligated Group" (the "CMHA Obligated Group") under the CMHA Bond Order. Members of the CMHA Obligated Group are jointly and severally liable for payment of CMHA Bonds and other obligations secured by the CMHA Bond Order ("Parity Obligations"). The CMHA Bond Order also authorizes the creation of a "Combined Group" (the "CMHA Combined Group"), which consists of the members of the CMHA Obligated Group and any affiliates designated by CMHA ("Designated Affiliates").

None of the Advocate Health JOA, the AAH System Entities, or any entities that are part of Wake Forest Baptist are members of the CMHA Combined Group as of the date of this report and, therefore, none of them have any obligation to provide for the payment of the CMHA Bonds or Parity Obligations.

#### **Basis of Presentation**

The accompanying consolidated financial statements and highlights reflect the financial position and results of operations of the CMHA Combined Group as of and for the six months ended June 30, 2023 and 2022. These financial statements have been prepared in accordance with U.S. generally accepted accounting principles, as promulgated by the Governmental Accounting Standards Board ("GASB").

## THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY COMBINED GROUP Financial Highlights

#### Six Months Ended June 30, 2023 Compared with Six Months Ended June 30, 2022:

For the six months ended June 30, 2023, net income was \$393,709, a \$1,545,481 increase from 2022, driven primarily by favorable investment performance and higher income from operations. Operating income was \$58,032 for the six months ended June 30, 2023, which was \$130,652 above the prior year.

Total operating revenue increased 12.5% to \$4,216,751 largely due to greater hospital and medical group patient volumes; annual increases in reimbursement rates; growth in retail pharmacy sales and additional grant revenue. Total operating expenses increased 8.9% to \$4,158,719, primarily due to personnel costs on higher patient volumes along with other expense inflation.

As of June 30, 2023, days cash on hand was 312 days. Debt-to-capitalization ratio decreased from 32.3% at December 31, 2022, to 30.7% at June 30, 2023, primarily driven by favorable net income in the first quarter.

# THE CMHA COMBINED GROUP COMBINED BALANCE SHEETS

	(Unaudited) June 30, 2023	(Audited) December 31, 2022
Assets	Julie 30, 2023	December 31, 2022
Current assets		
Cash and cash equivalents	\$ 329,566	\$ 402,408
Short term investments	30,948	31,546
Assets limited as to use	51,248	47,950
Patient accounts receivable	1,126,510	1,049,395
Other current assets	475,312	423,669
Total current assets	2,013,584	1,954,968
Other assets		
Assets limited as to use	6,001,845	5,946,372
Property and equipment, net	4,312,679	4,226,057
Operating lease right-of-use assets, net	475,431	483,250
Other noncurrent assets	341,644	319,403
Total other assets	11,131,599	10,975,082
Total assets	13,145,183	12,930,050
Deferred outflows of resources	243,967	165,439
Total assets and deferred outflows of resources	\$ 13,389,150	\$ 13,095,489
Liabilities		
Current liabilities		
Long-term debt, current portion	\$ 697,197	\$ 767,418
Operating lease liabilities, current portion	73,226	76,313
Accrued salaries and employee benefits	471,458	585,006
Accounts payable and other accrued liabilities	675,704	723,112
Estimated third party payer settlements	303,151	294,182
Total current liabilities	2,220,736	2,446,031
Noncurrent liabilities		
Long-term debt, less current portion	2,335,322	2,307,990
Operating lease liabilities, less current portion	441,829	443,075
Obligations under swap agreements	81,474	82,527
Other noncurrent liabilities	837,148	827,683
Total noncurrent liabilities	3,695,773	3,661,275
Total liabilities	5,916,509	6,107,306
Deferred inflows of resources	155,398	80,510
Net position		
Net investment in capital assets	1,310,995	1,123,938
Restricted - by donor	475,233	456,115
Unrestricted	5,531,015	5,327,620
Total net position	7,317,243	6,907,673
Total liabilities and deferred inflows and net position	\$ 13,389,150	\$ 13,095,489

# THE CMHA COMBINED GROUP COMBINED STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN NET POSITION

	(1	Unaudited)	(Unaudited)		
		Months Ended ne 30, 2023		Months Ended ne 30, 2022	
Revenue					
Patient service revenue	\$	3,792,392	\$	3,362,620	
Other revenue		424,359		384,504	
Total revenue		4,216,751		3,747,124	
Expenses					
Salaries, wages, and benefits		2,425,421		2,258,384	
Supplies and drugs		891,159		798,493	
Purchased services and other expenses		621,523		551,290	
Depreciation and amortization		220,616		211,577	
Total operating expenses		4,158,719		3,819,744	
Operating income (loss)		58,032		(72,620)	
Nonoperating income (loss)					
Interest expense		(64,508)		(54,806)	
Investment income (loss), net		447,611		(1,022,277)	
Other nonoperating loss, net		(47,426)		(2,069)	
Total nonoperating income (loss), net		335,677		(1,079,152)	
Excess (deficiency) of revenues and support over expenses and losses before contributions	\$	393,709	\$	(1,151,772)	
Changes in net position					
Capital and other contributions		15,861		9,423	
Changes in net position		409,570		(1,142,349)	
Net position, beginning of year		6,907,673		7,938,673	
Net position, end of year	\$	7,317,243	\$	6,796,324	

## THE CMHA COMBINED GROUP COMBINED STATEMENTS OF CASH FLOWS

Payments to suppliers		(Unaudited)		(1	(Unaudited)	
Receipts from third party payers and patients         \$ 3,724,247         \$ 3,299,417           Payments to suppliers         (1,566,379)         (1,512,770)           Payments to employees         (2,534,956)         (2,412,046)           Other receipts, net         365,558         24,817,77           Net cash used in operating activities         Settle payers         1,1570         (195,682)           Cash flows from innancing activities         Settle payers         1,100,000         (2,256,682) <td< th=""><th></th><th></th><th></th><th></th><th></th></td<>						
Payments to suppliers	Cash flows from operating activities					
Payments to employees	Receipts from third-party payers and patients	\$	3,724,247	\$	3,299,417	
Other receipts, net         365,558         428,717           Net cash lows from inparating activities         (11,570)         (196,682)           Cash flows from innancing activities         8           Retirements of commercial paper         (10,000)         —           Commitment to academic endowment fund         (47,000)         —           Other activities         (13,420)         (24,556)           Net cash used in noncapital financing activities         (290,004)         (288,924)           Cash flows from capital and related financing activities         (290,004)         (288,924)           Capital expenditures         (290,004)         (288,924)           Interest payments on short- and long-term debt         (61,047)         (59,162)           Repayments of long-term debt, net         (86,54)         (188,978)           Proceeds from issuance of long-term debt         (50,000)         143,064           Contributions restricted for building and equipment purchases         (37,37)         (37,970)           Net cash used in financing activities         (57,91)         (48,216)           Cash flows from investing activities         (57,91)         1,440           Purchase of investments and assets limited as to use         (57,91)         1,440           Purchase of investments and assets limited a	Payments to suppliers		(1,566,379)		(1,512,770)	
Net cash used in operating activities         (11,570)         (196,682)           Cash flows from financing activities         Cash flows from noncapital financing activities         (100,000)           Retirements of commercial paper         —         (100,000)           Commitment to academic endowment fund         (47,000)         —           Other activities         (60,420)         (102,456)           Net cash used in noncapital financing activities         (60,420)         (102,456)           Cash flows from capital and related financing activities         (290,004)         (288,924)           Interest payments on short and long-term debt         (61,047)         (59,162)           Repayments of long-term debt, net         (86,549)         (188,978)           Proceeds from issuance of long-term debt         (50,000)         143,064           Contributions restricted for building and equipment purchases         13,741         11,443           Other contributions         3,287         2,895           Net cash used in capital and related financing activities         (67,992)         (39,795)           Net cash used in capital and related financing activities         (67,992)         (39,751)           Investment earnings         (67,992)         (39,751)           Sales of investments and assets limited as to use         (48,01)	Payments to employees		(2,534,996)		(2,412,046)	
Cash flows from noncapital financing activities           Retirements of commercial paper         —         (100,000           Commitment to academic endowment fund         (47,000)         —           Other activities         (13,420)         (2,456           Net cash used in noncapital financing activities         (60,420)         (102,456           Cash flows from capital and related financing activities         (290,004)         (288,924           Capital expenditures         (290,004)         (188,978           Interest payments on short- and long-term debt         (51,047)         (55,162           Repayments of long-term debt, net         (85,69)         (188,978           Proceeds from Issuance of long-term debt         50,000         143,064           Contributions restricted for building and equipment purchases         (370,733)         (370,733)           Net cash used in financing activities         (370,733)         (379,707)           Net cash used in financing activities         (67,71)         (482,153)           Cash flows from investing activities         (67,79)         (39,751)           Investment earnings         6,771         1,440           Purchase of investments and assets limited as to use         (67,792)         (39,751)           Sales of investments and assets limited as to	Other receipts, net		365,558		428,717	
Cash flows from concapital financing activities         —         (100,000)           Retirements of commercial paper         —         (100,000)           Commitment to academic endowment fund         (47,000)         —           Other activities         (13,400)         (2,456)           Net cash used in noncapital financing activities         —         —           Cash flows from capital and related financing activities         (290,004)         (288,924)           Interest payments on short- and long-term debt         (61,047)         (59,162)           Repayments of long-term debt, net         (86,549)         (188,978)           Proceeds from issuance of long-term debt         50,000         143,064           Contributions restricted for building and equipment purchases         13,574         1,143           Other contributions         (370,739)         (379,739)         (379,739)           Net cash used in financing activities         (370,739)         (379,739)           Net cash used in financing activities         (67,972)         (37,513)           Investment earnings         6,771         1,440           Purchases of investments and assets limited as to use         (67,992)         (39,751)           Net cash provided by (used in) investing activities         (85,396)         (717,155)	Net cash used in operating activities		(11,570)		(196,682)	
Retirements of commercial paper         — (100,000 Commitment to academic endowment fund         (47,000)         — (24,506 Commitment to academic endowment fund         (47,000)         — (24,506 Commitment to academic endowment fund         (24,506 Commitment f	Cash flows from financing activities					
Commitment to academic endowment fund         (47,000)         2.45           Other activities         (13,420)         (2,456)           Net cash used in noncapital financing activities         (60,420)         (102,456)           Cash flows from capital and related financing activities         (290,004)         (288,924)           Capital expenditures         (290,004)         (58,924)           Interest payments on short- and long-term debt         (61,047)         (59,162)           Repayments of long-term debt, net         (80,549)         (188,978)           Porceeds from issuance of long-term debt         50,000         143,064           Contributions restricted for building and equipment purchases         3,287         2,859           Net cash used in inancing activities         (370,739)         (379,730)           Net cash used in investments and assets limited as to use         (67,992)         (39,751)           Investment earnings         (57,71         1,440           Purchase of investments and assets limited as to use         (38,30)         (71,715	Cash flows from noncapital financing activities					
Other activities         (13,420)         (2,456)           Net cash used in noncapital financing activities         (60,420)         (102,456)           Cash flows from capital and related financing activities         (290,004)         (288,924)           Capital expenditures         (290,004)         (288,924)           Interest payments on short- and long-term debt         (66,549)         (188,978)           Proceeds from issuance of long-term debt         50,000         143,064           Contributions restricted for building and equipment purchases         13,574         11,434           Other contributions         3,287         2,859           Net cash used in capital and related financing activities         (370,739)         (379,739)           Net cash used in financing activities         (431,159)         (482,163)           Cash flows from investing activities         6,771         1,440           Purchases of investments and assets limited as to use         6,791         1,440           Purchase of equity method investments         (19,957)         —           Net cash provided by (used in) investing activities         357,333         (38,311)           Net cash provided by (used in) investing activities         357,333         (38,311)           Reginning of year         486,680         1	Retirements of commercial paper		_		(100,000)	
Net cash used in noncapital financing activities         (60,420)         (102,456           Cash flows from capital and related financing activities         (290,004)         (288,924           Interest payments on short- and long-term debt         (61,047)         (59,162)           Repayments of long-term debt, net         (86,549)         (188,978           Proceeds from issuance of long-term debt permit purchases         50,000         143,064           Contributions restricted for building and equipment purchases         3,287         2,859           Net cash used in capital and related financing activities         (370,739)         379,707           Net cash used in financing activities         (431,159)         (482,163)           Cash flows from investing activities         (57,992)         (39,751)           Investment earnings         6,771         1,440           Purchases of investments and assets limited as to use         (57,992)         (39,751)           Sales of investments and assets limited as to use         (57,992)         (39,751)           Purchase of equity method investments         (85,396)         (71,715           Cash and cash equivalents         (85,396)         (71,715           Cash and cash equivalents         335,333         (38,311)           Net cash provided by (used in) investing activities	Commitment to academic endowment fund		(47,000)		_	
Cash flows from capital and related financing activities         (290,004)         (288,924 flower capital expenditures         (290,004)         (288,924 flower capital expenditures         (61,047)         (59,162 flower capital ca	Other activities		(13,420)		(2,456)	
Capital expenditures         (290,004)         (288,924           Interest payments on short- and long-term debt         (61,047)         (59,162           Repayments of long-term debt, net         (86,549)         (188,978           Proceeds from issuance of long-term debt         50,000         143,064           Contributions restricted for building and equipment purchases         13,574         1,143           Other contributions         3,287         2,289           Net cash used in capital and related financing activities         (307,339)         (379,707)           Net cash used in financing activities         (370,739)         (379,707)           Investment earnings         6,771         1,440           Purchases of investments and assets limited as to use         66,7992         (39,751           Sales of investments and assets limited as to use         438,011         —           Purchase of equity method investments         (59,492)         (39,751           Sales of investments and assets limited as to use         438,011         —           Purchase of lequity method investments         (59,493)         (38,311           Net decrease in cash, cash equivalents and restricted cash         (85,396)         (71,156           Cash and cash equivalents         329,566         1,66,44           <	Net cash used in noncapital financing activities		(60,420)		(102,456)	
Interest payments on short- and long-term debt         (61,047)         (59,162           Repayments of long-term debt, net         (86,549)         (188,978)           Proceeds from issuance of long-term debt         50,000         143,064           Contributions restricted for building and equipment purchases         13,574         11,434           Other contributions         3,287         2,859           Net cash used in capital and related financing activities         (370,739)         (379,707)           Net cash used in financing activities         6,771         1,440           Purchase of investments and assets limited as to use         6,771         1,440           Purchases of investments and assets limited as to use         438,011         -           Purchase of equity method investments         (19,457)         -           Purchase of equity method investments         (19,457)         -           Net cash provided by (used in) investing activities         357,333         (38,311)           Net cash provided by (used in) investing activities         (85,396)         (717,156           Cash and cash equivalents         (85,396)         1,019,470           End of period         \$ 486,680         1,019,470           End of period         \$ 232,566         1,8664           Restricted cash in	Cash flows from capital and related financing activities					
Repayments of long-term debt, net         (86,549)         (188,978)           Proceeds from issuance of long-term debt         50,000         13,064           Contributions restricted for building and equipment purchases         13,574         11,434           Other contributions         3,287         2,859           Net cash used in capital and related financing activities         (370,739)         (379,707)           Net cash used in financing activities         6,771         1,440           Investment earnings         6,771         1,440           Purchases of investments and assets limited as to use         (67,992)         (39,751)           Sales of investments and assets limited as to use         (67,992)         (39,751)           Sales of investments and assets limited as to use         (67,992)         (39,751)           Sales of investments and assets limited as to use         (67,992)         (39,751)           Sales of investments and assets limited as to use         (67,992)         (39,751)           Sale of investments and assets limited as to use         (67,992)         (39,751           Sale of investments and assets limited as to use         (88,391)         (71,156           Cash and cash equivalents         (88,5396)         (71,7156           Cash and cash equivalents and restricted cash         329,566	Capital expenditures		(290,004)		(288,924)	
Proceeds from issuance of long-term debt         50,000         143,064           Contributions restricted for building and equipment purchases         13,574         11,434           Other contributions         32,872         2,859           Net cash used in capital and related financing activities         (370,739)         (379,707)           Net cash used in financing activities         (431,159)         (482,163           Cash flows from investing activities           Investment earnings         6,771         1,440           Purchases of investments and assets limited as to use         438,011         −           Purchase of equity method investments         (19,457)         −           Purchase of equity method investments         (19,457)         −           Net cash provided by (used in) investing activities         357,333         (38,311           Net cash provided by (used in) investing activities         (85,396)         (717,156           Cash and cash equivalents           Beginning of year         486,680         1,019,470           End of period         \$ 401,284         302,314           Reconciliation of cash and cash equivalents to the balance sheet           Cash and cash equivalents and restricted cash         71,718         11,555           Total cash	Interest payments on short- and long-term debt		(61,047)		(59,162)	
Contributions restricted for building and equipment purchases         13,574         11,434           Other contributions         3,287         2,859           Net cash used in capital and related financing activities         (370,739)         (379,707)           Net cash used in financing activities         (370,339)         (393,707)           Cash flows from investing activities           Investment earnings         6,771         1,440           Purchases of investments and assets limited as to use         (67,992)         (39,751           Sales of investments and assets limited as to use         438,011         —           Purchase of equity method investments         (19,457)         —           Purchase of equity method investments         (35,333)         (38,311           Net cash provided by (used in) investing activities         357,333         (38,311           Net cash provided by (used in) investing activities         486,680         1,019,470           Easi and cash equivalents         486,680         1,019,470           End of period         \$ 401,284         \$ 302,314           Reconciliation of cash and cash equivalents to the balance sheet           Cash and cash equivalents         329,566         186,664           Restricted cash in investments and assets whose use is limited </td <td>Repayments of long-term debt, net</td> <td></td> <td>(86,549)</td> <td></td> <td>(188,978)</td>	Repayments of long-term debt, net		(86,549)		(188,978)	
Other contributions         3,287         2,859           Net cash used in capital and related financing activities         (370,739)         (379,707)           Net cash used in financing activities         (431,159)         (482,163)           Cash flows from investing activities           Investment earnings         6,771         1,440           Purchases of investments and assets limited as to use         (67,992)         (39,751)           Sales of investments and assets limited as to use         438,011         —           Purchase of equity method investments         (19,457)         —           Net cash provided by (used in) investing activities         357,333         (38,311)           Net decrease in cash, cash equivalents and restricted cash         (85,396)         (717,156           Cash and cash equivalents           Beginning of year         486,680         1,019,470           End of period         \$ 401,284         \$ 302,314           Reconciliation of cash and cash equivalents to the balance sheet           Cash and cash equivalents         329,566         186,664           Restricted cash in investments and assets whose use is limited         71,718         11,565           Total cash, cash equivalents and restricted cash         \$ 401,284         302,344	Proceeds from issuance of long-term debt		50,000		143,064	
Net cash used in capital and related financing activities         (370,739)         (379,707)           Net cash used in financing activities         (431,159)         (482,163)           Cash flows from investing activities           Investment earnings         6,771         1,440           Purchases of investments and assets limited as to use         (67,992)         (39,751)           Sales of investments and assets limited as to use         438,011         —           Purchase of equity method investments         (19,457)         —           Net cash provided by (used in) investing activities         357,333         (38,311)           Net decrease in cash, cash equivalents and restricted cash         85,396         717,156           Cash and cash equivalents           Beginning of year         486,680         1,019,470           End of period         \$401,284         \$302,314           Reconciliation of cash and cash equivalents to the balance sheet           Cash and cash equivalents         329,566         186,664           Restricted cash in investments and assets whose use is limited         71,718         115,650           Total cash, cash equivalents of certain gincome (loss) to net cash used in operating activities         \$8,802         \$120,616         211,577           Depreciating income (los	Contributions restricted for building and equipment purchases		13,574		11,434	
Net cash used in financing activities         (431,159)         (482,163)           Cash flows from investing activities         (5771)         1,440           Investment earnings         6,771         1,440           Purchases of investments and assets limited as to use         (67,992)         (39,751           Sales of investments and assets limited as to use         438,011         —           Purchase of equity method investments         (19,457)         —           Net cash provided by (used in) investing activities         357,333         (38,311)           Net decrease in cash, cash equivalents and restricted cash         (85,396)         (717,156)           Cash and cash equivalents         486,680         1,019,470           End of period         486,680         1,019,470           End of period         340,284         302,314           Reconciliation of cash and cash equivalents to the balance sheet           Cash and cash equivalents         329,566         186,664           Restricted cash in investments and assets whose use is limited         71,718         115,650           Total cash, cash equivalents and restricted cash         \$ 401,284         302,314           Reconciliation of operating income (loss) to net cash used in operating activities         \$ 58,032         \$ 72,620 <td< td=""><td>Other contributions</td><td></td><td>3,287</td><td></td><td>2,859</td></td<>	Other contributions		3,287		2,859	
Cash flows from investing activities	Net cash used in capital and related financing activities		(370,739)		(379,707)	
Investment earnings	Net cash used in financing activities		(431,159)		(482,163)	
Purchases of investments and assets limited as to use         (67,992)         (39,751           Sales of investments and assets limited as to use         438,011         —           Purchase of equity method investments         (19,457)         —           Net cash provided by (used in) investing activities         357,333         (38,311           Net decrease in cash, cash equivalents and restricted cash         (85,396)         (717,156)           Cash and cash equivalents         486,680         1,019,470           End of period         \$ 401,284         \$ 302,314           Reconciliation of cash and cash equivalents to the balance sheet         329,566         186,664           Restricted cash in investments and assets whose use is limited         71,718         115,650           Total cash, cash equivalents and restricted cash         \$ 401,284         \$ 302,314           Reconciliation of operating income (loss) to net cash used in operating activities         \$ 58,032         \$ (72,620           Adjustments to reconcile operating income (loss) to net cash used in operating activities         220,616         211,577           Increase in patient accounts receivable         (77,115)         (53,877           (Increase) decrease in other current assets         (45,934)         54,517           (Increase) decrease in other noncurrent assets         (75,881)	Cash flows from investing activities					
Sales of investments and assets limited as to use Purchase of equity method investments Net cash provided by (used in) investing activities Net cash provided by (used in) investing activities Net decrease in cash, cash equivalents and restricted cash Reginning of year End of period  Reconciliation of cash and cash equivalents to the balance sheet Cash and cash equivalents Restricted cash in investments and assets whose use is limited Total cash, cash equivalents and restricted cash  Reconciliation of operating income (loss) to net cash used in operating activities Operating income (loss)  Perpeciation and amortization Depreciation and amortization Increase in patient accounts receivable (Increase) decrease in other noncurrent assets (Increase) decrease in other noncurrent assets (Increase) decrease in other noncurrent liabilities (Increase) (decrease) in estimated third party payer settlements (Increase (decrease) in estimated third party payer settlements (Increase) (decrease) in estimated third party payer settlements	Investment earnings		6,771		1,440	
Purchase of equity method investments         (19,457)         —           Net cash provided by (used in) investing activities         357,333         (38,311)           Net decrease in cash, cash equivalents and restricted cash         (85,396)         (717,156)           Cash and cash equivalents         486,680         1,019,470           End of period         \$ 401,284         \$ 302,314           Reconcilitation of cash and cash equivalents to the balance sheet         \$ 401,284         \$ 302,314           Cash and cash equivalents         329,566         186,664           Restricted cash in investments and assets whose use is limited         71,718         115,650           Total cash, cash equivalents and restricted cash         \$ 401,284         \$ 302,314           Reconcilitation of operating income (loss) to net cash used in operating activities         \$ 58,032         \$ 72,620           Adjustments to reconcile operating income (loss) to net cash used in operating activities         \$ 58,032         \$ 72,620           Adjustments to reconcile operating income (loss) to net cash used in operating activities         \$ 58,032         \$ 72,620           Increase in patient accounts receivable         777,115         53,877           (Increase) decrease in other current assets         45,934         54,517           (Increase) decrease in other noncurrent assets <td< td=""><td>Purchases of investments and assets limited as to use</td><td></td><td>(67,992)</td><td></td><td>(39,751)</td></td<>	Purchases of investments and assets limited as to use		(67,992)		(39,751)	
Net cash provided by (used in) investing activities         357,333         (38,311           Net decrease in cash, cash equivalents and restricted cash         (85,396)         (717,156)           Cash and cash equivalents         486,680         1,019,470           End of period         \$ 401,284         \$ 302,314           Reconciliation of cash and cash equivalents to the balance sheet         329,566         186,664           Restricted cash in investments and assets whose use is limited         71,718         115,650           Total cash, cash equivalents and restricted cash         \$ 401,284         \$ 302,314           Reconciliation of operating income (loss) to net cash used in operating activities         \$ 58,032         \$ 72,260           Adjustments to reconcile operating income (loss) to net cash used in operating activities         220,616         211,577           Increase in patient accounts receivable         (77,115)         (53,877           (Increase) decrease in other current assets         (45,934)         54,517           Decrease in accounts payable and other accrued liabilities         (103,697)         (318,817           Increase (decrease) in other noncurrent liabilities         3,440         (163,653           Increase (decrease) in estimated third party payer settlements         8,969         (9,326	Sales of investments and assets limited as to use		438,011		_	
Net decrease in cash, cash equivalents and restricted cash(85,396)(717,156)Cash and cash equivalents486,6801,019,470Beginning of year486,6801,019,470End of period\$ 401,284\$ 302,314Reconciliation of cash and cash equivalents to the balance sheet329,566186,664Cash and cash equivalents329,566186,664Restricted cash in investments and assets whose use is limited71,718115,650Total cash, cash equivalents and restricted cash\$ 401,284\$ 302,314Reconciliation of operating income (loss) to net cash used in operating activities\$ 58,032\$ (72,620Adjustments to reconcile operating income (loss) to net cash used in operating activities220,616211,577Increase in patient accounts receivable(77,115)(53,877(Increase) decrease in other current assets(45,934)54,517(Increase) decrease in other noncurrent assets(75,881)155,517Decrease in accounts payable and other accrued liabilities(103,697)318,817Increase (decrease) in other noncurrent liabilities3,440(163,653)Increase (decrease) in estimated third party payer settlements8,969(9,326)	Purchase of equity method investments		(19,457)		_	
Cash and cash equivalents  Beginning of year 486,680 1,019,470  End of period \$486,680 1,019,470  End of period \$401,284 \$302,314  Reconciliation of cash and cash equivalents to the balance sheet  Cash and cash equivalents 329,566 186,664  Restricted cash in investments and assets whose use is limited 71,718 115,650  Total cash, cash equivalents and restricted cash \$401,284 \$302,314  Reconciliation of operating income (loss) to net cash used in operating activities  Operating income (loss) \$58,032 \$(72,620)  Adjustments to reconcile operating income (loss) to net cash used in operating activities  Depreciation and amortization 220,616 211,577  Increase in patient accounts receivable (77,115) (53,877)  (Increase) decrease in other current assets (45,934) 54,517  (Increase) decrease in other noncurrent assets (75,881) 155,517  Decrease in accounts payable and other accrued liabilities (103,697) (318,817)  Increase (decrease) in other noncurrent liabilities 3,440 (163,653)  Increase (decrease) in estimated third party payer settlements 8,969 (9,326)	Net cash provided by (used in) investing activities		357,333		(38,311)	
Beginning of year486,6801,019,470End of period\$ 401,284302,314Reconciliation of cash and cash equivalents to the balance sheet329,566186,664Cash and cash equivalents329,566186,664Restricted cash in investments and assets whose use is limited71,718115,650Total cash, cash equivalents and restricted cash\$ 401,284302,314Reconciliation of operating income (loss) to net cash used in operating activities\$ 58,032\$ (72,620)Operating income (loss)\$ 58,032\$ (72,620)Adjustments to reconcile operating income (loss) to net cash used in operating activities\$ 220,616211,577Increase in patient accounts receivable(77,115)(53,877(Increase) decrease in other current assets(45,934)54,517(Increase) decrease in other noncurrent assets(75,881)155,517Decrease in accounts payable and other accrued liabilities(103,697)(318,817Increase (decrease) in other noncurrent liabilities3,440(163,653)Increase (decrease) in estimated third party payer settlements8,969(9,326)	Net decrease in cash, cash equivalents and restricted cash		(85,396)		(717,156)	
End of period\$ 401,284\$ 302,314Reconciliation of cash and cash equivalents to the balance sheet329,566186,664Cash and cash equivalents329,566186,664Restricted cash in investments and assets whose use is limited71,718115,650Total cash, cash equivalents and restricted cash\$ 401,284\$ 302,314Reconciliation of operating income (loss) to net cash used in operating activitiesOperating income (loss)\$ 58,032\$ (72,620)Adjustments to reconcile operating income (loss) to net cash used in operating activities220,616211,577Increase in patient accounts receivable(77,115)(53,877)(Increase) decrease in other current assets(45,934)54,517(Increase) decrease in other noncurrent assets(75,881)155,517Decrease in accounts payable and other accrued liabilities(103,697)(318,817)Increase (decrease) in other noncurrent liabilities3,440(163,653)Increase (decrease) in estimated third party payer settlements8,969(9,326)	Cash and cash equivalents					
Reconciliation of cash and cash equivalents to the balance sheet  Cash and cash equivalents Restricted cash in investments and assets whose use is limited  Total cash, cash equivalents and restricted cash  Total cash, cash equivalents and restricted cash  Reconciliation of operating income (loss) to net cash used in operating activities  Operating income (loss)  Adjustments to reconcile operating income (loss) to net cash used in operating activities  Depreciation and amortization  Depreciation and amortization  Increase in patient accounts receivable  (Increase) decrease in other current assets  (Increase) decrease in other noncurrent assets  (Increase) decrease in other noncurrent assets  (Increase) decrease in other noncurrent liabilities  Decrease in accounts payable and other accrued liabilities  Increase (decrease) in other noncurrent liabilities  (Increase) (decrease) in estimated third party payer settlements  Reconciliation of 2329,566  186,664  186,664  186,664  186,664  186,664  191,5550  192,050  193,050  193,050  193,050  193,060  193,060  193,060  193,060	Beginning of year		486,680		1,019,470	
Cash and cash equivalents329,566186,664Restricted cash in investments and assets whose use is limited71,718115,650Total cash, cash equivalents and restricted cash\$ 401,284\$ 302,314Reconciliation of operating income (loss) to net cash used in operating activities\$ 58,032\$ (72,620)Operating income (loss)\$ 58,032\$ (72,620)Adjustments to reconcile operating income (loss) to net cash used in operating activities220,616211,577Increase in patient accounts receivable(77,115)(53,877)(Increase) decrease in other current assets(45,934)54,517(Increase) decrease in other noncurrent assets(75,881)155,517Decrease in accounts payable and other accrued liabilities(103,697)(318,817)Increase (decrease) in other noncurrent liabilities3,440(163,653)Increase (decrease) in estimated third party payer settlements8,969(9,326)	End of period	\$	401,284	\$	302,314	
Restricted cash in investments and assets whose use is limited Total cash, cash equivalents and restricted cash  Reconciliation of operating income (loss) to net cash used in operating activities  Operating income (loss) Adjustments to reconcile operating income (loss) to net cash used in operating activities  Depreciation and amortization Depreciation and amortization Increase in patient accounts receivable (Increase) decrease in other current assets (Increase) decrease in other noncurrent assets (Increase) decrease in accounts payable and other accrued liabilities Increase (decrease) in other noncurrent liabilities (Increase) decrease) in estimated third party payer settlements (Increase) decrease) (Increase) decrease) in estimated third party payer settlements (Increase) decrease) (Increase) d	Reconciliation of cash and cash equivalents to the balance sheet					
Total cash, cash equivalents and restricted cash\$ 401,284\$ 302,314Reconciliation of operating income (loss) to net cash used in operating activities\$ 58,032\$ (72,620)Operating income (loss)\$ 58,032\$ (72,620)Adjustments to reconcile operating income (loss) to net cash used in operating activities\$ 220,616211,577Depreciation and amortization220,616211,577Increase in patient accounts receivable(77,115)(53,877)(Increase) decrease in other current assets(45,934)54,517(Increase) decrease in other noncurrent assets(75,881)155,517Decrease in accounts payable and other accrued liabilities(103,697)(318,817)Increase (decrease) in other noncurrent liabilities3,440(163,653)Increase (decrease) in estimated third party payer settlements8,969(9,326)	Cash and cash equivalents		329,566		186,664	
Total cash, cash equivalents and restricted cash\$ 401,284\$ 302,314Reconciliation of operating income (loss) to net cash used in operating activities\$ 58,032\$ (72,620)Operating income (loss)\$ 58,032\$ (72,620)Adjustments to reconcile operating income (loss) to net cash used in operating activities\$ 220,616211,577Depreciation and amortization220,616211,577Increase in patient accounts receivable(77,115)(53,877)(Increase) decrease in other current assets(45,934)54,517(Increase) decrease in other noncurrent assets(75,881)155,517Decrease in accounts payable and other accrued liabilities(103,697)(318,817)Increase (decrease) in other noncurrent liabilities3,440(163,653)Increase (decrease) in estimated third party payer settlements8,969(9,326)	Restricted cash in investments and assets whose use is limited		71,718		115,650	
Operating income (loss) \$ 58,032 \$ (72,620) Adjustments to reconcile operating income (loss) to net cash used in operating activities  Depreciation and amortization 220,616 211,577  Increase in patient accounts receivable (77,115) (53,877) (Increase) decrease in other current assets (45,934) 54,517 (Increase) decrease in other noncurrent assets (75,881) 155,517  Decrease in accounts payable and other accrued liabilities (103,697) (318,817) Increase (decrease) in other noncurrent liabilities 3,440 (163,653) Increase (decrease) in estimated third party payer settlements 8,969 (9,326)	Total cash, cash equivalents and restricted cash	\$	401,284	\$	302,314	
Adjustments to reconcile operating income (loss) to net cash used in operating activities  Depreciation and amortization  Increase in patient accounts receivable (Increase) decrease in other current assets (Increase) decrease in other noncurrent assets (Increase) decrease in other noncurrent assets (75,881) Decrease in accounts payable and other accrued liabilities (103,697) Increase (decrease) in other noncurrent liabilities (103,653) Increase (decrease) in estimated third party payer settlements	Reconciliation of operating income (loss) to net cash used in operating activities					
Depreciation and amortization220,616211,577Increase in patient accounts receivable(77,115)(53,877(Increase) decrease in other current assets(45,934)54,517(Increase) decrease in other noncurrent assets(75,881)155,517Decrease in accounts payable and other accrued liabilities(103,697)(318,817Increase (decrease) in other noncurrent liabilities3,440(163,653)Increase (decrease) in estimated third party payer settlements8,969(9,326)	Operating income (loss)	\$	58,032	\$	(72,620)	
Increase in patient accounts receivable(77,115)(53,877(Increase) decrease in other current assets(45,934)54,517(Increase) decrease in other noncurrent assets(75,881)155,517Decrease in accounts payable and other accrued liabilities(103,697)(318,817Increase (decrease) in other noncurrent liabilities3,440(163,653)Increase (decrease) in estimated third party payer settlements8,969(9,326)	Adjustments to reconcile operating income (loss) to net cash used in operating activities					
(Increase) decrease in other current assets(45,934)54,517(Increase) decrease in other noncurrent assets(75,881)155,517Decrease in accounts payable and other accrued liabilities(103,697)(318,817Increase (decrease) in other noncurrent liabilities3,440(163,653Increase (decrease) in estimated third party payer settlements8,969(9,326)	Depreciation and amortization		220,616		211,577	
(Increase) decrease in other current assets(45,934)54,517(Increase) decrease in other noncurrent assets(75,881)155,517Decrease in accounts payable and other accrued liabilities(103,697)(318,817Increase (decrease) in other noncurrent liabilities3,440(163,653Increase (decrease) in estimated third party payer settlements8,969(9,326)	Increase in patient accounts receivable		(77,115)		(53,877)	
Decrease in accounts payable and other accrued liabilities (103,697) (318,817 Increase (decrease) in other noncurrent liabilities 3,440 (163,653 Increase (decrease) in estimated third party payer settlements 8,969 (9,326)	(Increase) decrease in other current assets		(45,934)		54,517	
Decrease in accounts payable and other accrued liabilities (103,697) (318,817 Increase (decrease) in other noncurrent liabilities 3,440 (163,653 Increase (decrease) in estimated third party payer settlements 8,969 (9,326)					155,517	
Increase (decrease) in other noncurrent liabilities3,440(163,653Increase (decrease) in estimated third party payer settlements8,969(9,326)	Decrease in accounts payable and other accrued liabilities				(318,817)	
Increase (decrease) in estimated third party payer settlements 8,969 (9,326)	• •				(163,653)	
					(9,326)	
	Net cash used in operating activities	\$	(11,570)	\$	(196,682)	

## THE CMHA COMBINED GROUP UTILIZATION STATISTICS

	Six Months Ended June 30, 2023	Six Months Ended June 30, 2022	Change	% Change
Medical Group				
Practice locations	546	542	4	0.7 %
Total Physicians	1,865	1,839	26	1.4 %
Patient visits (including faculty)	3,091,400	2,885,922	205,478	7.1 %
Total Acute Care Facilities				
Adjusted patient days (excluding newborn)	964,757	912,133	52,624	5.8 %
Adjusted discharges (excluding newborn)	168,066	148,247	19,819	13.4 %
Surgical Procedures	51,293	46,764	4,529	9.7 %



#### ATRIUM HEALTH WAKE FOREST BAPTIST

Introduction

#### **Atrium Health Wake Forest Baptist Combined Group**

Atrium Health Wake Forest Baptist is an integrated clinical, research, and academic enterprise operated by Wake Forest University Baptist Medical Center, a North Carolina nonprofit corporation ("WFBMC"), which is a joint operating company that was established by Wake Forest University, a North Carolina nonprofit corporation ("WFU"), and North Carolina Baptist Hospital, a North Carolina nonprofit corporation ("NCBH"). Wake Forest University Health Sciences ("WFUHS") is a wholly-owned affiliate of WFU that owns all of the assets of and operates Wake Forest University School of Medicine and is part of Atrium Health Wake Forest Baptist.

WFBMC, NCBH, and WFUHS are the members of the "Obligated Group" (the "WFB Obligated Group") created under a Master Trust Indenture, dated as of March 1, 2010 (as supplemented and amended, the "WFB Master Indenture"), between NCBH and The Bank of New York Mellon Trust Company, N.A., as master trustee. The members of the WFB Obligated Group are jointly and severally liable on any "Obligations" issued under the WFB Master Indenture. The WFB Master Indenture authorizes the creation of a "Combined Group" (the "WFB Combined Group"), which consists of the members of the WFB Obligated Group and all "Designated Members." Wake Forest University is not a member of the WFB Obligated Group or a part of Wake Forest Baptist and is not directly or indirectly obligated to pay amounts due with respect to Obligations issued under the WFB Master Indenture.

None of the Advocate Health JOA, the AAH System Entities, or CMHA or any of its affiliates are members of the WFB Combined Group as of the date of this report and, therefore, none of them have any obligation to provide for the payment of any Obligation issued under the WFB Master Indenture.

#### **Basis of Presentation**

The accompanying combined financial statements reflect the financial position and results of operations of Atrium Health Wake Forest Baptist as of and for the six months ended June 30, 2023 and 2022. These financial statements have been prepared in accordance with U.S. generally accepted accounting principles, as promulgated by the Financial Accounting Standards Board ("FASB").

# ATRIUM HEALTH WAKE FOREST BAPTIST COMBINED BALANCE SHEETS

	-	Jnaudited) ne 30, 2023	(Audited) mber 31, 2022
Assets			 
Current assets			
Cash and cash equivalents	\$	251,698	\$ 320,705
Patient receivables, net		424,553	393,740
Accounts, grants, and note receivable, net		200,905	166,860
Other current assets		94,656	106,701
Total current assets		971,812	988,006
Property and equipment, net		1,276,450	1,260,602
Investments and assets limited as to use		2,164,487	2,098,334
Operating lease right-of-use assets		144,226	157,902
Other assets		176,210	174,550
Total assets	\$	4,733,185	\$ 4,679,394
Liabilities			
Current liabilities			
Accounts payable	\$	186,522	\$ 189,755
Salaries and benefits payable		356,217	385,169
Other liabilities and accruals		200,774	190,905
Estimated third party payer settlements		34,860	40,725
Current portion of operating lease liabilities		33,225	36,335
Current portion of long-term debt		54,175	54,468
Total current liabilities		865,773	897,357
Notes payable, finance leases, and lines of credit, net of current portion		75,087	79,350
Bonds payable, net of current portion		789,398	806,950
Operating lease liabilities, net of current portion		118,260	128,896
Interest rate swap liability		996	1,181
Retirement benefits		90,134	90,646
Other liabilities		149,915	100,620
Total liabilities		2,089,563	2,105,000
Net assets			
Without donor restrictions		2,229,667	2,182,915
With donor restrictions		413,955	391,479
Total net assets		2,643,622	2,574,394
Total liabilities and net assets	\$	4,733,185	\$ 4,679,394

# ATRIUM HEALTH WAKE FOREST BAPTIST COMBINED STATEMENT OF OPERATIONS AND CHANGES IN NET ASSETS

	(Unaudited)	(Unaudited)		
	Six Months Ended June 30, 2023	Six Months Ended June 30, 2022		
Revenue				
Patient service revenue	\$ 1,848,710	\$ 1,614,550		
Other sources	494,879	440,516		
Total operating revenues	2,343,589	2,055,066		
Expenses				
Personnel costs	1,404,604	1,265,770		
Supplies	577,994	509,348		
Purchased services	71,619	76,574		
Other operating expenses	209,328	193,547		
Depreciation and amortization	77,601	81,928		
Financing costs	16,867	14,940		
Total operating expenses	2,358,013	2,142,107		
Operating loss	(14,424)	(87,041)		
Nonoperating income (loss)				
Investment income (loss), net	63,597	(190,856)		
Unrealized gains on interest rate swap valuation	185	1,585		
Pension and postretirement costs	1,085	157		
Losses from equity method affiliates	(2,855)	(933)		
Other, net	(268)	(867)		
Total nonoperating income (loss), net	61,744	(190,914)		
Excess (deficiency) of revenues and gains over expenses and losses	47,320	(277,955)		
Changes in net assets without donor restrictions				
Pension and postretirement-related (losses) gains other than net periodic cost	(568)	4,291		
Change in net assets without donor restrictions	46,752	(273,664)		
Changes in net assets with donor restrictions				
Contributions	43,201	18,677		
Investment return in excess of amounts designated for current operations	5,086	4,366		
Net assets released from restrictions	(29,613)	(26,502)		
Net investment gains (losses)	4,604	(22,679)		
Other	(802)	(15)		
Change in net assets with donor restrictions	22,476	(26,153)		
Change in total net assets	69,228	(299,817)		
Net assets, beginning of year	2,574,394	2,816,937		
Net assets, end of year	\$ 2,643,622	\$ 2,517,120		

## ATRIUM HEALTH WAKE FOREST BAPTIST COMBINED STATEMENTS OF CASH FLOWS

	(u	Inaudited)	(Unaudited)		
		Nonths Ended ne 30, 2023		Nonths Ended ne 30, 2022	
Cash flows from operating activities					
Receipts from third-party payers and patients	\$	1,812,032	\$	1,624,154	
Payments to suppliers		(840,882)		(825,468)	
Payments to employees		(1,433,551)		(1,323,221)	
Other receipts, net		482,999		395,211	
Net cash provided by (used in) operating activities		20,598		(129,324)	
Cash flows from financing activities					
Principal payments, refunding, and retirements on short and long-term debt		(20,225)		(20,180)	
Payments on finance lease obligations		(1,424)		(1,357)	
Other contributions		2,460		4,327	
Net cash used in financing activities		(19,189)		(17,210)	
Cash flows from investing activities					
Net purchases and sales of investments and assets whose use is limited		41,026		105,216	
Purchases of property and equipment		(93,405)		(62,982)	
Net cash (used in) provided by investing activities		(52,379)		42,234	
Net decrease in cash, cash equivalents, and restricted cash		(50,970)		(104,300)	
Cash, cash equivalents, and restricted cash					
Beginning of year		323,502		338,517	
End of year	\$	272,532	\$	234,217	
Reconciliation of cash, cash equivalents, and restricted cash to the balance sheet					
Cash and cash equivalents		251,698		229,921	
Restricted cash in investments and assets whose use is limited		20,834		4,296	
Total cash, cash equivalents, and restricted cash	\$	272,532	\$	234,217	

# ATRIUM HEALTH WAKE FOREST BAPTIST COMBINING BALANCE SHEET INFORMATION (Unaudited)

	June 30, 2023										
	Atrium Health Wake Forest Baptist		Atrium Health Wake Forest Baptist Non- Combined Group		Atrium Health Wake Forest Wake Forest Baptist Non-		Atrium Health Wake Forest Wake Forest Baptist Non-		Eliminations		rium Health Take Forest ist Combined Group
Assets											
Current assets											
Cash and cash equivalents	\$	251,698	\$	(43,076)	\$	_	\$	208,622			
Patient receivables, net		424,553		(24,637)		_		399,916			
Accounts, grants, and note receivable, net		200,905		(43,131)		_		157,774			
Other current assets		94,656		(4,989)		_		89,667			
Total current assets		971,812		(115,833)		_		855,979			
Property and equipment, net		1,276,450		(79,898)		_		1,196,552			
Investments and assets limited as to use		2,164,487		(109,271)		(4,328)		2,050,888			
Operating lease right-of-use assets		144,226		(26,146)		_		118,080			
Other assets		176,210		(92,492)		_		83,718			
Total assets	\$	4,733,185	\$	(423,640)	\$	(4,328)	\$	4,305,217			
Liabilities											
Current liabilities											
Accounts payable	\$	186,522	\$	(179,029)	\$	_	\$	7,493			
Salaries and benefits payable		356,217		(12,495)		_		343,722			
Other liabilities and accruals		200,774		(10,171)		_		190,603			
Estimated third party payer settlements		34,860		(10,285)		_		24,575			
Current portion of operating lease liabilities		33,225		(6,011)		_		27,214			
Current portion of long-term debt		54,175		(1,377)		_		52,798			
Total current liabilities		865,773		(219,368)		_		646,405			
Notes payable, finance leases, and lines of credit, net of current portion		75,087		(22,831)		_		52,256			
Bonds payable, net of current portion		789,398		_		_		789,398			
Operating lease liabilities, net of current portion		118,260		(21,286)		_		96,974			
Interest rate swap liability		996		_		_		996			
Retirement benefits		90,134		(1,301)		_		88,833			
Other liabilities		149,915		(3,895)		_		146,020			
Total liabilities		2,089,563		(268,681)				1,820,882			
Net assets											
Without donor restrictions		2,229,667		(155,954)		(4,328)		2,069,385			
With donor restrictions		413,955		995				414,950			
Total net assets		2,643,622		(154,959)		(4,328)		2,484,335			
Total liabilities and net assets	\$	4,733,185	\$	(423,640)	\$	(4,328)	\$	4,305,217			

# ATRIUM HEALTH WAKE FOREST BAPTIST COMBINING STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS (Unaudited)

	Six Months Ended June 30, 2023								
		rium Health /ake Forest Baptist	W Ba	ium Health ake Forest optist Non- bined Group	Elii	Eliminations		Atrium Health Wake Forest Baptist Combined Group	
Revenue									
Patient service revenue	\$	1,848,710	\$	(131,058)	\$	_	\$	1,717,652	
Other sources		494,879		(43,387)		583		452,075	
Total operating revenues		2,343,589		(174,445)		583		2,169,727	
Expenses									
Personnel costs		1,404,604		(98,950)		_		1,305,654	
Supplies		577,994		(23,727)		_		554,267	
Purchased services		71,619		(5,972)		583		66,230	
Other operating expenses		209,328		(47,412)		_		161,916	
Depreciation and amortization		77,601		(3,536)		_		74,065	
Financing costs		16,867		(483)		_		16,384	
Total operating expenses		2,358,013		(180,080)		583		2,178,516	
Operating (loss) income		(14,424)		5,635		_		(8,789)	
Nonoperating income (loss)									
Investment income (loss), net		63,597		(3,391)		_		60,206	
Unrealized gains on interest rate swap valuation		185		_		_		185	
Pension and postretirement costs		1,085		(103)		_		982	
Losses from equity method affiliates		(2,855)		(235)		(8,737)		(11,827)	
Other, net		(268)		2,205		(1,645)		292	
Total nonoperating income (loss), net		61,744		(1,524)		(10,382)		49,838	
Excess (deficiency) of revenues and gains over expenses and losses	\$	47,320	\$	4,111	\$	(10,382)	\$	41,049	
Changes in net assets without donor restrictions									
Pension and postretirement-related losses other than net periodic cost		(568)		_				(568)	
Change in net assets without donor restrictions		46,752		4,111		(10,382)		40,481	
Changes in net assets with donor restrictions									
Contributions		43,201		989		_		44,190	
Investment return in excess of amounts designated for current operations		5,086		_		_		5,086	
Net assets released from restrictions		(29,613)		_		_		(29,613)	
Net investment gains		4,604		_		_		4,604	
Other		(802)		_		_		(802)	
Change in net assets with donor restrictions		22,476		989		_		23,465	
Change in total net assets		69,228		5,100		(10,382)		63,946	
Net assets, beginning of year		2,574,394		(160,059)		6,054		2,420,389	
Net assets, end of year	\$	2,643,622	\$	(154,959)	\$	(4,328)	\$	2,484,335	

## ATRIUM HEALTH WAKE FOREST BAPTIST COMBINED GROUP UTILIZATION STATISTICS

	Six Months Ended June 30, 2023	Six Months Ended June 30, 2022	Change	% Change
Case Mix Adjusted Equivalent Discharges	154,237	140,865	13,372	9.5 %
Patient Days	172,418	160,999	11,419	7.1 %
Inpatient Admissions	31,678	28,737	2,941	10.2 %
Average Length of Stay	5.44	5.60	(0.16)	(2.9)%
Average Length of Stay (Case Mix Adjusted)	2.80	2.83	(0.03)	(1.1)%
Inpatient Operating Room Cases	9,572	8,726	846	9.7 %
Outpatient Operating Room Cases	22,449	21,331	1,118	5.2 %
Total Operating Room Cases	32,021	30,057	1,964	6.5 %
Emergency Department Visits	107,305	98,739	8,566	8.7 %
Case Mix Index (all payors using Medicare weights)	1.9437	1.9788	(0.0351)	(1.8)%
RVUs	4,998,036	4,145,664	852,372	20.6 %
Outpatient Visit	1,033,921	955,515	78,406	8.2 %